The Use of Low Molecular Weight Heparin in Traumatic Brain Injury

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the safety and efficacy of early administration of Low Molecular Weight Heparin to patients with traumatic brain injury.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hennepin Healthcare Research Institute; Minneapolis Medical Research Foundation
• Collaborator: Aventis Pharmaceuticals
• Treatments: Dalteparin; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight

Criteria

Inclusion Criteria:

• Blunt traumatic brain injury (Marshall II-V)

• Stable 6 hr. head CT

• Stable hemoglobin

Exclusion Criteria:

• Premorbid coagulopathy

• Pregnancy

• < 18 y.o.

• Need for therapeutic anticoagulation

• Heparin allergy